Description

Tesamorelin is a stabilized synthetic analogue of growth hormone-releasing hormone (GHRH) widely researched for its potent stimulation of endogenous growth hormone secretion and its distinctive influence on visceral adipose tissue reduction pathways. Unlike peptide secretagogues that act via ghrelin receptors, Tesamorelin directly engages GHRH receptors on pituitary somatotroph cells, making it a targeted research tool for hypothalamic-pituitary-somatotropic axis studies. Research into Tesamorelin frequently examines its metabolic effects, including GH-mediated lipolysis, visceral fat modulation, and IGF-1 stimulation. It has also been studied in the context of cognitive function, HIV-associated lipodystrophy models, and body composition research. The 20mg formulation provides a standard analytical concentration suitable for a broad range of endocrine and metabolic research protocols.